Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:CERCNASDAQ:EOLSNASDAQ:EVLONASDAQ:TLC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCERCCerecor$15.94+6.4%$2.60$1.98▼$4.50$1.53B1.441.27 million shs78,100 shsEOLSEvolus$11.43-0.3%$13.43$7.07▼$15.43$662.25M1.45610,462 shs248,985 shsEVLOEvelo Biosciences$0.05$0.05$0.03▼$13.93$940K2.0340,657 shs31,190 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+199.13%CERCCerecor+15.23%+24.73%+223.95%+236.63%+404.38%EOLSEvolus-0.35%-0.87%-17.26%-4.02%+36.27%EVLOEvelo Biosciences+3.39%-8.60%-8.60%-29.69%-97.72%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AN/AN/AN/AEOLSEvolus3.9891 of 5 stars3.52.00.03.52.52.50.6EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsideCERCCerecorN/AN/AN/AN/AEOLSEvolus3.00Buy$20.6080.23% UpsideEVLOEvelo Biosciences2.00HoldN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/ACurrent Analyst RatingsLatest EOLS, EVLO, CERC, TLC, and AGLE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/1/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.001/29/2024EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00CERCCerecor$6.70M228.42N/AN/A$0.22 per share72.45EOLSEvolus$202.09M3.28N/AN/A($0.36) per share-31.75EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/ATLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ACERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AEOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/7/2024 (Confirmed)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest EOLS, EVLO, CERC, TLC, and AGLE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AEOLSEvolus-$0.0650N/A+$0.0650N/AN/AN/A 3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59CERCCerecor0.792.192.18EOLSEvolusN/A2.332.10EVLOEvelo BiosciencesN/A0.480.48TLCTaiwan Liposome0.673.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ACERCCerecor62.84%EOLSEvolus90.69%EVLOEvelo Biosciences0.31%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%CERCCerecor45.70%EOLSEvolus5.40%EVLOEvelo Biosciences1.02%TLCTaiwan LiposomeN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableCERCCerecor3196.01 millionN/ANot OptionableEOLSEvolus27357.94 million54.82 millionOptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableEOLS, EVLO, CERC, TLC, and AGLE HeadlinesSourceHeadlineBack for More! TLC’s ‘MILF Manor’ Returns for Season 2: Meet the Cast Ahead of the Premiere Dateyahoo.com - April 26 at 5:11 PMAngela Deem accuses TLC of forcing her to 'keep her mouth shut' in unhinged rantmsn.com - April 23 at 11:14 PMHow to watch TLC’s ‘Little People, Big World’ new episodes free April 23masslive.com - April 23 at 6:13 PMWhy Kody Brown is the Most Disliked TLC Villain of All Timeyahoo.com - April 21 at 12:36 PM'I end up pooping myself on stage,' man cries after botched weight loss surgery in new TLC showmsn.com - April 19 at 10:23 AM‘7 Little Johnstons’ Season 14: How to watch episode 6 on TLC for freemsn.com - April 16 at 7:23 PMMonday: ‘Seeking Sister Wife’ Season 5, episode 7: How to watch TLC online for freecleveland.com - April 15 at 7:49 PMSee inside three-bed end terrace on sale for just £35k, but it needs serious TLCmsn.com - April 15 at 9:47 AMThe Disco Biscuits Nod To OutKast, TLC, Gucci Mane, & More In Atlanta [Video/Audio]liveforlivemusic.com - April 14 at 6:18 PMRico Wade, legendary Atlanta producer who worked with OutKast and co-wrote TLC's 'Waterfalls,' dies at 52msn.com - April 13 at 8:27 PMRico Wade, TLC ‘Waterfalls’ Cowriter and Southern Rap Trailblazer, Dies at 52thewrap.com - April 13 at 3:27 PMMorris continues new Brooks-TLC pleaobservertoday.com - April 12 at 8:34 AMTLC starts $27m upgradeaustralianageingagenda.com.au - April 11 at 8:17 PMTLC donates to Clatsop Animal Assistancedailyastorian.com - April 11 at 10:16 AMTLC Should Cancel ‘Sister Wives’ After Garrison Brown’s Suicidemsn.com - April 10 at 6:46 PMHow to watch TLC’s ‘Take My Tumor’ season 1, episode 2, stream for freepennlive.com - April 10 at 1:45 PMCrimestoppers seek tips on $500+ equipment theft from TLC Tree Service in Pananewschannel20.com - April 9 at 3:11 PM‘Seeking Sister Wife’ Season 5, episode 6: How to watch TLC online for freecleveland.com - April 8 at 7:40 PMHow to watch TLC’s ‘Seeking Sister Wife’ new episode free Monday, April 8masslive.com - April 8 at 7:40 PM'OutDaughtered' and 'Doubling Down With the Derricos' Finally Returning to TLC—See the Exclusive Teasersmsn.com - April 8 at 2:39 PMTLC is coming to the 2024 Wisconsin State Fair, with Jordin Sparks opening the concertmsn.com - April 8 at 2:39 PMFans Rejoice as ‘OutDaughtered’ and ‘Doubling Down With the Derricos’ Set to Premiere New Seasons on TLCmsn.com - April 8 at 2:39 PM2024 Wisconsin State Fair: TLC takes Main Stageyahoo.com - April 8 at 9:39 AM2024 Wisconsin State Fair: TLC takes Main Stage, Aug. 2fox6now.com - April 8 at 9:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.CerecorNASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Taiwan LiposomeNASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.